Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.

× No keyword cloud information.

4 in total

1. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors: Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal: BMJ Date: 2002-06-01

2. Efficacy and safety of COX 2 inhibitors.

Authors: Roger Jones
Journal: BMJ Date: 2002-09-21

3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

Review 4. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Authors: Jonathan J Deeks; Lesley A Smith; Matthew D Bradley
Journal: BMJ Date: 2002-09-21

4 in total

Review 1. COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

Authors: Samir Malhotra; N Shafiq; P Pandhi
Journal: MedGenMed Date: 2004-03-23

Review 2. Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

Authors: Helmut Schmidt; Barry G Woodcock; Gerd Geisslinger
Journal: Drug Saf Date: 2004 Impact factor: 5.606

Review 3. Celecoxib for osteoarthritis.

Authors: Livia Puljak; Ana Marin; Davorka Vrdoljak; Filipa Markotic; Ana Utrobicic; Peter Tugwell
Journal: Cochrane Database Syst Rev Date: 2017-05-22

4. An economic model of long-term use of celecoxib in patients with osteoarthritis.

Authors: Michael Loyd; Dale Rublee; Philip Jacobs
Journal: BMC Gastroenterol Date: 2007-07-04 Impact factor: 3.067

4 in total